Improving prostate cancer screening using genetic factors
Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen Levels
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11168619
This study is looking to make prostate cancer screening better by using genetic information to help tell the difference between high PSA levels caused by serious cancer and those from non-cancer issues, so patients can get more accurate results and only the care they really need.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11168619 on ClinicalTrials.gov |
What this research studies
This research aims to enhance prostate cancer screening by integrating genetic factors into the assessment of prostate-specific antigen (PSA) levels. The approach focuses on distinguishing between high PSA levels caused by aggressive cancer and those due to non-cancerous conditions. By refining polygenic risk scores (PRS) for prostate cancer, the study seeks to improve the prediction of aggressive disease, thereby reducing the risks of overdiagnosis and overtreatment. Patients may benefit from a more accurate screening process that better identifies those who truly need intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research are men undergoing PSA screening, particularly those with elevated PSA levels.
Not a fit: Patients who have already been diagnosed with aggressive prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate prostate cancer screenings, reducing unnecessary treatments and improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using genetic factors to improve cancer screening, indicating that this approach has potential for success.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WITTE, JOHN S. — STANFORD UNIVERSITY
- Study coordinator: WITTE, JOHN S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.